Acorda Rises 9.7 Percent After FDA Gives Nod for Parkinson's Therapy

(Bloomberg) -- Acorda Therapeutics Inc. rose the most since October after the U.S. Food and Drug Administration approved its therapy for Parkinson’s disease.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.